S6 Kinase

Choose Selective S6 Kinase Inhibitors

S6 Kinase Signaling Pathway Map

S6 Kinase Signaling Pathways

S6 Kinase Products

  • All (18)
  • S6 Kinase Inhibitors (16)
  • S6 Kinase Antibodies (2)
  • New S6 Kinase Products
Catalog No. Product Name Information Product Use Citations Product Validations
S0385 S6K-18 S6K-18 is a highly selective inhibitor of ribosomal protein S6 kinase beta-1 (S6K1, p70S6K, p70-S6K).
S1014 Bosutinib (SKI-606) Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy.
J Immunother Cancer, 2022, 10(1)e003766
Front Oncol, 2022, 12:802482
Mol Pharmacol, 2022, MOLPHARM-AR-2021-000287
S1421 Staurosporine (AM-2282) Staurosporine (AM-2282, Antibiotic AM-2282, STS) is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
Cancer Res, 2022, canres.0218.2021
Neurotherapeutics, 2022, 10.1007/s13311-022-01212-z
Anal Chem, 2022, 10.1021/acs.analchem.1c05455
S1558 AT7867 AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM in cell-free assays, respectively; little activity outside the AGC kinase family.
Cancers (Basel), 2021, 13(6)1205
Cell Chem Biol, 2020, S2451-9456(20)30340-8
FEBS J, 2019, 10.1111/febs.15112
S1582 H 89 2HCl H 89 2HCl is a potent PKA inhibitor with Ki of 48 nM in a cell-free assay, 10-fold selective for PKA than PKG,500-fold greater selectivity than PKC, MLCK, calmodulin kinase II and casein kinase I/II. H 89 2HCl induces autophagy.
Signal Transduct Target Ther, 2022, 7(1):46
Elife, 2022, 11e72266
Int J Biol Sci, 2022, 18(5):2047-2059
S2163 PF-4708671 PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.
Nat Commun, 2022, 13(1):1548
Blood Cancer J, 2022, 12(3):39
Oncogene, 2022, 10.1038/s41388-021-02155-z
S2843 BI-D1870 BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B. BI-D1870 exhibits anticancer attributes including the generation of reactive oxygen species (ROS) and increases in endoplasmic reticulum (ER) stress and autophagy.
Cancer Sci, 2022, 113(1):132-144
EMBO J, 2021, 40(7):e106106
Cell Rep, 2021, 37(12):110137
S3940 3'-Hydroxypterostilbene 3'-Hydroxypterostilbene (3'-HPT) is one of the active constituents of Sphaerophysa salsula and Pterocarpus marsupium which may be useful in treating different types of haematological malignancies. 3'-Hydroxypterostilbene, a natural pterostilbene analogue, effectively inhibits the growth of human colon cancer cells (IC50s of 9.0, 40.2, and 70.9 µM for COLO 205, HCT-116, and HT-29 cells, respectively) by inducing apoptosis and autophagy. 3'-Hydroxypterostilbene inhibits the PI3K/Akt/mTOR/p70S6K, and p38MAPK pathways and activates the ERK1/2, JNK1/2 MAPK pathways.
S6385New Prexasertib (LY2606368)

Prexasertib (LY2606368, ACR 368) is a selective ATP competitor inhibitor of Chk1 and Chk2 with IC50s of 1 nM and 8 nM in cell-free assays, respectively. Prexasertib also inhibits RSK1 with an IC50 of 9 nM in cell-free assay.

J Exp Clin Cancer Res, 2022, 41(1):141
Cell, 2021, 184(25):6119-6137.e26
ACS Pharmacol Transl Sci, 2021, 4(4):1449-1461
S7563 AT13148 AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.
Br J Cancer, 2021, 10.1038/s41416-021-01442-6
Sci Rep, 2021, 11(1):18532
Cell, 2020, 182(3):685-712.e19
S7698 LY2584702 LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
Front Immunol, 2022, 13:821932
Cell Signal, 2022, 94:110311
Cell, 2021, 184(25):6193-6206.e14
S7704 LY2584702 Tosylate LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
Front Immunol, 2022, 13:821932
Cell Signal, 2022, 94:110311
PLoS Comput Biol, 2021, 17(6):e1009125
S7752 Pluripotin (SC1) Pluripotin (SC1) is a dual inhibitor of extracellular signal-regulated kinase 1 (ERK1, MAPK3) and RasGAP. Maintains embryonic stem cell (ESC) self-renewal. Pluripotin also inhibits RSK1, RSK2, RSK3 and RSK4 with IC50 of 0.5 µM, 2.5 µM, 3.3 µM and 10.0 µM, respectively.
Antiviral Res, 2018, 157:57-67
Reprod Domest Anim, 2018, 53(5):1052-1059
S7870 LJH685 LJH685 is a potent pan-RSK inhibitor with IC50 of 6 nM, 5 nM and 4 nM for RSK1, RSK2, and RSK3, respectively.
Cell Rep, 2022, 38(11):110522
Mol Cell, 2021, S1097-2765(21)00736-X
EMBO Mol Med, 2020, 12(4):e11177
S7871 LJI308 LJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.
Cell, 2020, 182(3):685-712.e19
Cell, 2020, 182(3):685-712.e19
Cancer Discov, 2019, 9(2):264-281
S8518 AD80 AD80, a multikinase inhibitor, shows strong activity against human RET (c-RET), BRAF, S6K, and SRC but were much less active than either AD57 or AD58 against mTOR. The IC50 value for RET is 4 nM.
Mol Cancer Res, 2020, 1176-1188
Mol Cancer Res, 2020, 18(8):1176-1188
Mol Cancer Res, 2020, 27;molcanres.1245.2019
A5033 Phospho-S6K1(T421/S424) Rabbit Recombinant mAb

Phospho-S6K1(T421/S424) Rabbit Recombinant mAb detects endogenous levels of Phospho-S6K1(T421/S424).

Mol Cancer Ther, 2021, molcanther.MCT-21-0395-A.2021
A5269 Tuberin Rabbit Recombinant mAb Tuberin Rabbit Recombinant mAb detects endogenous level of total Tuberin.
S0385 S6K-18 S6K-18 is a highly selective inhibitor of ribosomal protein S6 kinase beta-1 (S6K1, p70S6K, p70-S6K).
S1014 Bosutinib (SKI-606) Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy.
J Immunother Cancer, 2022, 10(1)e003766
Front Oncol, 2022, 12:802482
Mol Pharmacol, 2022, MOLPHARM-AR-2021-000287
S1421 Staurosporine (AM-2282) Staurosporine (AM-2282, Antibiotic AM-2282, STS) is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
Cancer Res, 2022, canres.0218.2021
Neurotherapeutics, 2022, 10.1007/s13311-022-01212-z
Anal Chem, 2022, 10.1021/acs.analchem.1c05455
S1558 AT7867 AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM in cell-free assays, respectively; little activity outside the AGC kinase family.
Cancers (Basel), 2021, 13(6)1205
Cell Chem Biol, 2020, S2451-9456(20)30340-8
FEBS J, 2019, 10.1111/febs.15112
S1582 H 89 2HCl H 89 2HCl is a potent PKA inhibitor with Ki of 48 nM in a cell-free assay, 10-fold selective for PKA than PKG,500-fold greater selectivity than PKC, MLCK, calmodulin kinase II and casein kinase I/II. H 89 2HCl induces autophagy.
Signal Transduct Target Ther, 2022, 7(1):46
Elife, 2022, 11e72266
Int J Biol Sci, 2022, 18(5):2047-2059
S2163 PF-4708671 PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.
Nat Commun, 2022, 13(1):1548
Blood Cancer J, 2022, 12(3):39
Oncogene, 2022, 10.1038/s41388-021-02155-z
S2843 BI-D1870 BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B. BI-D1870 exhibits anticancer attributes including the generation of reactive oxygen species (ROS) and increases in endoplasmic reticulum (ER) stress and autophagy.
Cancer Sci, 2022, 113(1):132-144
EMBO J, 2021, 40(7):e106106
Cell Rep, 2021, 37(12):110137
S3940 3'-Hydroxypterostilbene 3'-Hydroxypterostilbene (3'-HPT) is one of the active constituents of Sphaerophysa salsula and Pterocarpus marsupium which may be useful in treating different types of haematological malignancies. 3'-Hydroxypterostilbene, a natural pterostilbene analogue, effectively inhibits the growth of human colon cancer cells (IC50s of 9.0, 40.2, and 70.9 µM for COLO 205, HCT-116, and HT-29 cells, respectively) by inducing apoptosis and autophagy. 3'-Hydroxypterostilbene inhibits the PI3K/Akt/mTOR/p70S6K, and p38MAPK pathways and activates the ERK1/2, JNK1/2 MAPK pathways.
S6385New Prexasertib (LY2606368)

Prexasertib (LY2606368, ACR 368) is a selective ATP competitor inhibitor of Chk1 and Chk2 with IC50s of 1 nM and 8 nM in cell-free assays, respectively. Prexasertib also inhibits RSK1 with an IC50 of 9 nM in cell-free assay.

J Exp Clin Cancer Res, 2022, 41(1):141
Cell, 2021, 184(25):6119-6137.e26
ACS Pharmacol Transl Sci, 2021, 4(4):1449-1461
S7563 AT13148 AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.
Br J Cancer, 2021, 10.1038/s41416-021-01442-6
Sci Rep, 2021, 11(1):18532
Cell, 2020, 182(3):685-712.e19
S7698 LY2584702 LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
Front Immunol, 2022, 13:821932
Cell Signal, 2022, 94:110311
Cell, 2021, 184(25):6193-6206.e14
S7704 LY2584702 Tosylate LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
Front Immunol, 2022, 13:821932
Cell Signal, 2022, 94:110311
PLoS Comput Biol, 2021, 17(6):e1009125
S7752 Pluripotin (SC1) Pluripotin (SC1) is a dual inhibitor of extracellular signal-regulated kinase 1 (ERK1, MAPK3) and RasGAP. Maintains embryonic stem cell (ESC) self-renewal. Pluripotin also inhibits RSK1, RSK2, RSK3 and RSK4 with IC50 of 0.5 µM, 2.5 µM, 3.3 µM and 10.0 µM, respectively.
Antiviral Res, 2018, 157:57-67
Reprod Domest Anim, 2018, 53(5):1052-1059
S7870 LJH685 LJH685 is a potent pan-RSK inhibitor with IC50 of 6 nM, 5 nM and 4 nM for RSK1, RSK2, and RSK3, respectively.
Cell Rep, 2022, 38(11):110522
Mol Cell, 2021, S1097-2765(21)00736-X
EMBO Mol Med, 2020, 12(4):e11177
S7871 LJI308 LJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.
Cell, 2020, 182(3):685-712.e19
Cell, 2020, 182(3):685-712.e19
Cancer Discov, 2019, 9(2):264-281
S8518 AD80 AD80, a multikinase inhibitor, shows strong activity against human RET (c-RET), BRAF, S6K, and SRC but were much less active than either AD57 or AD58 against mTOR. The IC50 value for RET is 4 nM.
Mol Cancer Res, 2020, 1176-1188
Mol Cancer Res, 2020, 18(8):1176-1188
Mol Cancer Res, 2020, 27;molcanres.1245.2019
A5033 Phospho-S6K1(T421/S424) Rabbit Recombinant mAb

Phospho-S6K1(T421/S424) Rabbit Recombinant mAb detects endogenous levels of Phospho-S6K1(T421/S424).

Mol Cancer Ther, 2021, molcanther.MCT-21-0395-A.2021
A5269 Tuberin Rabbit Recombinant mAb Tuberin Rabbit Recombinant mAb detects endogenous level of total Tuberin.
S6385New Prexasertib (LY2606368)

Prexasertib (LY2606368, ACR 368) is a selective ATP competitor inhibitor of Chk1 and Chk2 with IC50s of 1 nM and 8 nM in cell-free assays, respectively. Prexasertib also inhibits RSK1 with an IC50 of 9 nM in cell-free assay.

J Exp Clin Cancer Res, 2022, 41(1):141
Cell, 2021, 184(25):6119-6137.e26
ACS Pharmacol Transl Sci, 2021, 4(4):1449-1461